Importantly, pancreatitis severity and EGFR hyperactivation were attenuated by the treatment of mice with anti–CA19-9 blocking antibodies, including the fully human 5B1 clone (Weitzenfeld et al., 2019), highlighting a glycosylation-based therapeutic vulnerability in pancreatitis and PDA. This evidence concerns the gene EGFR and pancreatitis.